Abstract:BackgroundCrohn's disease (CD) is a chronic nonspecific inflammatory bowel disease (IBD) with an increasing incidence worldwide. The etiology of CD is still obscure, but microbial dysbiosis has been recognized as an essential factor contributing to CD. However, few studies have revealed the microbiome's signatures and reciprocal correlations between multiple sites in patients with CD over different disease stages. This study investigated the specific microbial architectures of the oral cavity, sputum, and ileum in patients with CD in the active and remission stages. MethodsMicrobial samples from the oral cavity, sputum, and ileum were collected from patients with CD in the active and remission stages and healthy controls. The microbial composition was assessed by 16S ribosomal RNA (rRNA) gene sequencing. In addition, bioinformatics methods were used to demonstrate the microbial signatures, functional changes, and correlations between microbiota and clinical data in CD. ResultsCompared with healthy controls, a distinct microbiota dysbiosis in the oral cavity, sputum, and ileum of patients with CD was identified, characterized by alterations in microbiota biodiversity and composition. The oral cavity and sputum microbiota showed significantly lower microbial diversity in patients with CD than in healthy controls. In terms of microbiota composition, the microbiota changes in the oral cavity of patients with CD were similar to those in the sputum, while they were different from those in the ileum. In the oral cavity and sputum of patients with CD, a lower relative abundance of Firmicutes and Actinobacteria was observed compared to healthy controls, which was most prominent in the active stage. In contrast, an increased relative abundance of Fusobacteria, Porphyromonas, and Haemophilus was observed in patients with CD. The predicted metabolic pathways involved in the oral cavity, sputum, and ileum were similar, predominantly involving metabolism, environmental information processing, and genetic information processing. ConclusionThe results revealed the alterations of microbiota architecture in the oral cavity, sputum, and ileum of patients with CD, which varied across disease stages. Studying microbiota dysbiosis may bring new insights into the etiology of CD and lead to novel treatments.

Integrative Multi-Omics Deciphers the Spatial Characteristics of Host-Gut Microbiota Interactions in Crohn’s Disease

Two Distinct Metacommunities Characterize the Gut Microbiota in Crohn'S Disease Patients

Characterization of Specific Signatures of the Oral Cavity, Sputum, and Ileum Microbiota in Patients With Crohn's Disease

Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases

Multi-Omics Characterization of Colon Mucosa and Submucosa/Wall from Crohn’s Disease Patients

Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease

Integrative Analysis of Transcriptomic and Proteomic Profiling in Inflammatory Bowel Disease Colon Biopsies

The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon

Integration of Taxa Abundance and Occurrence Frequency to Identify Key Gut Bacteria Correlated to Clinics in Crohn's Disease.

Microbiome and Metabolome Features in Inflammatory Bowel Disease Via Multi-Omics Integration Analyses Across Cohorts

Role of gut microbiota in Crohn's disease pathogenesis: Insights from fecal microbiota transplantation in mouse model

Inter-kingdom relationships in Crohn's disease explored using a multi-omics approach

Correlation between altered gut microbiota and elevated inflammation markers in patients with Crohn’s disease

Bacterial microbiome profiles of the inflamed terminal ileum mucosa in active Crohn’s disease patients

Microbiota in Mesenteric Adipose Tissue from Crohn's Disease Promote Colitis in Mice

Bacterial Characteristics of Intestinal Tissues from Patients with Crohn’s Disease

Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn’s disease

Gut microbiome structure and metabolic activity in inflammatory bowel disease

Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease

Molecular-Phylogenetic Characterization of the Microbiota in Ulcerated and Non-Ulcerated Regions in the Patients with Crohn's Disease

Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease.